Summary: CytoReason launches LINA AI Agent with NVIDIA

Why It Matters: CytoReason is moving from static disease models to active AI agents. By partnering with NVIDIA, they are signaling a major increase in the speed and computing power available for drug research.

What Changed:

• Announced a new product called LINA, an AI Agent for Pharma R&D.
• Highlighted that LINA is "accelerated by NVIDIA."
• Updated the news section to prioritize the January 12th, 2026 press release.
• Reorganized the "In the news" section to show the Sanofi collaboration and NVIDIA NIM coverage as secondary items.